UK biotech Tiziana Life Sciences (AIM:TILS) has announced the purchase of key assets from Shardna, a biobanking and genomics research company from Sardinia, an Italian island known for its large population of people living to an advanced age.
Tiziana, which is focused on targeted drugs to treat diseases in oncology and immunology, has also established an Italian subsidiary in Sardinia, LonGevia Genomics Srl.
The role of this subsidiary is to develop the acquired assets to identify novel drug targets and diagnostic applications, and the research has a particular benefit owing to Sardinia’s thriving older age group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze